Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

International researchers warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly. The mpox virus has mutated, and the ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

Here we go again. From the New York Health Department: Anyone Who Ate Food From ilili Restaurant During January 31 – February ...

Sparked by a flurry of executive orders in the first week of taking power, and evolving at dizzying pace, the new US administration has taken a wrecking ball to health-related services and research ...

The global secretariat of the Global Validation Advisory Committee (GVAC) on the validation of elimination of mother-to-child ...